Aclaris Therapeutics, Inc.
ACRSDrugs in Pipeline
19
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ACRS Earnings Report
EPS Est: $-0.16 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ACRS's past catalysts played out
A-101
Common Wart
Active
Common Wart
A-101 Solution
Seborrheic Keratosis
ATI-045
Atopic Dermatitis
ATI-1777
Atopic Dermatitis
A-101 Vehicle
Seborrheic Keratosis
A-101 Topical Solution 40%
Dermatosis Papulosa Nigra
ATI-450 50 mg oral tablet BID
Rheumatoid Arthritis
A-101 Topical Solution
Common Wart
ATI-501 400mg BID (Low dose)
Alopecia
ATI-50002 topical solution
Vitiligo
A-101 25%
Seborrheic Keratosis (SK)
ATI-2138
Atopic Dermatitis
ATI-50002
Androgenetic Alopecia
A-101 Vehicle Solution
Common Wart
ATI-1777 2.0% w/w
Atopic Dermatitis
A-101 Solution 40
Common Warts
ATI-450
Rheumatoid Arthritis
ATI-502
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
A-101 | Phase 3 | Common Wart | - | - |
Active | Phase 3 | Common Wart | - | |
A-101 Solution | Phase 3 | Seborrheic Keratosis | - | - |
ATI-045 | Phase 2 | Atopic Dermatitis | - | - |
ATI-1777 | Phase 2 | Atopic Dermatitis | - | - |
A-101 Vehicle | Phase 2 | Seborrheic Keratosis | - | - |
A-101 Topical Solution 40% | Phase 2 | Dermatosis Papulosa Nigra | - | - |
ATI-450 50 mg oral tablet BID | Phase 2 | Rheumatoid Arthritis | - | - |
A-101 Topical Solution | Phase 2 | Common Wart | - | - |
ATI-501 400mg BID (Low dose) | Phase 2 | Alopecia | - | - |
ATI-50002 topical solution | Phase 2 | Vitiligo | - | - |
A-101 25% | Phase 2 | Seborrheic Keratosis (SK) | - | - |
ATI-2138 | Phase 2 | Atopic Dermatitis | - | - |
ATI-50002 | Phase 2 | Androgenetic Alopecia | - | - |
A-101 Vehicle Solution | Phase 2 | Common Wart | - | - |
ATI-1777 2.0% w/w | Phase 2 | Atopic Dermatitis | - | - |
A-101 Solution 40 | Phase 2 | Common Warts | - | - |
ATI-450 | Phase 2 | Rheumatoid Arthritis | - | - |
ATI-502 | Phase 2 | Atopic Dermatitis | - | - |
Atopic Dermatitis
5 drugs in this indication
Common Wart
4 drugs in this indication
Rheumatoid Arthritis
2 drugs in this indication
Seborrheic Keratosis
2 drugs in this indication
Alopecia Universalis (AU)
1 drug in this indication
Dermatosis Papulosa Nigra
1 drug in this indication
Alopecia
1 drug in this indication
Vitiligo
1 drug in this indication
Seborrheic Keratosis (SK)
1 drug in this indication
Androgenetic Alopecia
1 drug in this indication
Common Warts
1 drug in this indication
Hidradenitis Suppurativa
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aclaris Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in Aclaris Therapeutics, Inc.'s (ACRS) pipeline across Phase 3, Phase 2. Its lead program is A-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aclaris Therapeutics, Inc.'s next FDA catalyst?→
Aclaris Therapeutics, Inc.'s (ACRS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACRS biotech catalysts?→
Add ACRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aclaris Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.